Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ranolazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ranolazine SCHEMBL124665 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL6391141 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL1495098 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL30296819 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL7933344 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL124666 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL612077 | 0.99 | LMNA (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL14841986 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL230758 | 0.99 | LMNA (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL3462812 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6TSHRNFKB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021078987-A1 | COMBINATION TREATMENTS FOR CANCER | Celex Oncology Innovations Limited (GB) | 2021-04-29 | — | — | WO | claimed |
| EP-2861254-B1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | ACESION PHARMA APS (DK) | 2020-04-29 | — | — | EP | claimed |
| EP-4118430-A1 | MEASURING THE ELECTRIC ACTIVITY OF CELLS FOR THE EVALUATION OF METASTATIC POTENTIAL OF CANCER CELLS | Celex Oncology Innovations Limited (GB) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021180685-A1 | MEASURING THE ELECTRIC ACTIVITY OF CELLS FOR THE EVALUATION OF METASTATIC POTENTIAL OF CANCER CELLS | Celex Oncology Innovations Limited (GB) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021078987-A1 | COMBINATION TREATMENTS FOR CANCER | Celex Oncology Innovations Limited (GB) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021036230-A1 | RANOLAZINE SUSTAINED-RELEASE COMPOSITION AND PREPARATION METHOD THEREFOR | 深圳翰宇药业股份有限公司 | 2021-03-04 | — | — | WO | disclosed |
| EP-2480234-B1 | SUSTAINED RELEASE COMPOSITION OF RANOLAZINE | LUPIN LTD (IN) | 2020-02-26 | — | — | EP | disclosed |
| EP-2480234-A2 | SUSTAINED RELEASE COMPOSITION OF RANOLAZINE | Lupin Limited (IN) | 2012-08-01 | — | — | EP | disclosed |
| US-20120177729-A1 | SUSTAINED RELEASE COMPOSITION OF RANOLAZINE | LUPIN LIMITED (IN) | 2012-07-12 | — | — | US | disclosed |
| WO-2011036677-A2 | SUSTAINED RELEASE COMPOSITION OF RANOLAZINE | LUPIN LIMITED (IN) | 2011-03-31 | — | — | WO | disclosed |
| EP-2252294-A1 | USE OF RANOLAZINE FOR TREATING PAIN | Gilead Sciences, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20010047000-A1 | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | GILEAD SCIENCES, INC. | 2001-11-29 | — | — | US | disclosed |
| US-6303607-B1 | ADMINISTERING SUSTAINED RELEASE PHARMACEUTICAL DOSAGE FORM INCLUDING RANOLAZINE, PH-DEPENDENT AND PH-INDEPENDENT BINDERS TO HUMAN SUFFERING FROM VARIANT OR EXCERCISE-INDUCED ANGINA | CV THERAPEUTICS, INC. | 2001-10-16 | — | — | US | disclosed |
| WO-2001066093-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001060348-A2 | PARTIAL FATTY ACID OXIDATION INHIBITORS IN THE TREATMENT OF CONGESTIVE HEART FAILURE | CV THERAPEUTICS, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-1109558-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1096937-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000013686-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000013687-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| EP-0126449-A1 | Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry | SYNTEX (U.S.A.) INC. (US) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047000-A1 | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | FABP3, COXFA4, CPT2 | SCN5A 2041/4885CYP3A4 616/4885CYP2D6 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.